The emerging role of heparanase in cardiovascular diseases: Pathophysiology, clinical outcomes, and therapeutic perspectives [0.03%]
肝糖胺聚糖酶在心血管疾病中作用的研究进展：病理生理、临床预后和治疗前景
Emrah Bayam,Macit Kalçık,Ahmet Seyfeddin Gürbüz et al.
Emrah Bayam et al.
Sonothrombolysis as an adjunct to primary PCI in STEMI: a systematic review and meta-analysis of randomized trials [0.03%]
溶栓疗法作为STEMI直接PCI辅助治疗的系统评价和Meta分析研究
Shree Rath,Ahmad Omar Saleh,Osama Ahmad et al.
Shree Rath et al.
This study evaluates the role of ultrasound-mediated thrombolysis (sonothrombolysis) as an adjunct to percutaneous coronary intervention (PCI) in patients with ST-elevated myocardial infarction (STEMI). A comprehensive literature search was...
Thrombus histopathology in distal versus proximal vessel occlusion: insights and future directions for stroke reperfusion [0.03%]
远端与近端血管闭塞的血栓病理学：卒中再灌注的见解和未来方向
Senta Frol,Bernard R Bendok
Senta Frol
Acute ischemic stroke is a leading cause of disability and death worldwide. This commentary highlights the role of thrombus composition in influencing treatment outcomes and therapeutic strategies. Rapid reperfusion through intravenous thro...
Toward platelet-count-adaptive anticoagulation in cancer thrombocytopenia: a standards-first, equity-aware proposal [0.03%]
面向癌症血小板减少症的血小板计数适应性抗凝：一种以标准为主导、注重公平性的建议
M Vijayasimha
M Vijayasimha
Cancer-associated thrombosis (CAT) with thrombocytopenia (TP) poses concurrent risks of bleeding and recurrence. Guidance is fragmented by nonuniform platelet thresholds, tumor-context effects on agent choice, and scarce prospective data fo...
miR-493-3p alleviates carotid artery stenosis by targeting YTHDF2 [0.03%]
microRNA-493-3p通过靶向YTHDF2缓解颈动脉狭窄
Chenghao Li,Shuo Sun,Kaijie Yu et al.
Chenghao Li et al.
Refining the evidence base for anticoagulation in HALT following TAVR [0.03%]
经导管主动脉瓣置换术后的无抗凝疗法后再栓塞事件的循证研究改进
Spencer Ng,John P Vavalle
Spencer Ng
Oxidized phospholipids on plasminogen are associated with reduced platelet surface marker expression and intrinsic reactivity [0.03%]
与血浆甘氨肽结合的氧化磷脂降低血小板表面标记物表达和固有反应性
Alexander Kille,Klaus Kaier,Thomas Nührenberg et al.
Alexander Kille et al.
Impact of biological age versus chronological age on clinical outcomes in patients with atrial fibrillation: insights from the COOL-AF registry [0.03%]
生物年龄与心房颤动患者的临床结局之间的关系——COOL-AF注册研究的新认识
Rungroj Krittayaphong,Pongsakorn Buraphat,Ahthit Yindeengam et al.
Rungroj Krittayaphong et al.
Because patients with atrial fibrillation (AF) often exhibit heterogeneous risks that are not fully captured by traditional clinical factors, identifying a more accurate measure of physiological ageing could improve risk stratification and ...
Comparison of activated and 4-factor prothrombin complex concentrates for reversal of apixaban- and rivaroxaban-associated major bleeding [0.03%]
活化四因子凝血酶复合物与普洛特酶复合物逆转阿哌沙班和利伐沙班所致大出血的比较研究
R Monroe Crawley,Marwan Sheikh-Taha
R Monroe Crawley
Factor Xa inhibitor (FXaI)-associated major bleeding presents a critical management challenge. Although andexanet alfa is the targeted reversal agent, its limited availability and high cost has sustained the use of prothrombin complex conce...
Association of factor V leiden and ischemic stroke in young adults: a national inpatient sample analysis [0.03%]
因因子V莱顿突变和年轻成人缺血性卒中的关联：基于全国住院样本的分析
Jagkirat Singh,Ryan W Walters,Jack T Rausch et al.
Jagkirat Singh et al.
The association between Factor V Leiden (FVL) and ischemic stroke in young adults remains uncertain. We compared the prevalence of FVL coding in ischemic stroke versus non-stroke hospitalizations and examined in-hospital outcomes among youn...